Simplex Trading
KLRS

Simplex Trading’s Kalaris Therapeutics KLRS Stock Holding History

Simplex Trading’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-72
Closed -$2.84K – 10045
2023
Q3 		$3K Buy
+72
New +$4.91K ﹤0.01% 7984
2023
Q2 		– Sell
-107
Closed -$10.2K – 10150
2023
Q1 		$9K Sell
107
-127
-54% -$16.2K ﹤0.01% 7667
2022
Q4 		$27K Buy
234
+209
+836% +$35.4K ﹤0.01% 6589
2022
Q3 		$4K Buy
+25
New +$3.9K ﹤0.01% 8993
2022
Q1 		– Sell
-378
Closed -$112K – 11584
2021
Q4 		$112K Buy
378
+374
+9,350% +$174K ﹤0.01% 6073
2021
Q3 		$2K Hold
4
– – ﹤0.01% 9581
2021
Q2 		$1K Sell
4
-20
-83% -$10.3K ﹤0.01% 9874
2021
Q1 		$12K Buy
+24
New +$20.2K ﹤0.01% 7818
2020
Q4 		– Sell
-5
Closed -$3.85K – 9223
2020
Q3 		$3K Buy
+5
New +$3.42K ﹤0.01% 7338

Other funds holding KLRS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Simplex Trading's KLRS Position: Q4 2023 in Review

Simplex Trading sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 72 shares — an estimated $2.84K sold.

Simplex Trading first reported a position in KLRS in Q3 2020 and held it in 9 quarters. The position peaked at $112K in Q4 2021. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • Simplex Trading reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Simplex Trading sold 72 Kalaris Therapeutics shares in Q4 2023, an estimated $2.84K.
  • Simplex Trading first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 9 quarters.
  • Simplex Trading's Kalaris Therapeutics position peaked at $112K in Q4 2021.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on Simplex Trading's 13F filing for Q4 2023, filed 2 Feb 2024.